Key Laboratory of Human Functional Genomics of Jiangsu Province, Nanjing Medical University, Nanjing, Jiangsu 211166, China
2.
State Key Laboratory of Reproductive Medicine, Clinical Center of Reproductive Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China
3.
Department of Cell Biology, Nanjing Medical University, Nanjing, Jiangsu 211166, China
Funds:
This study was supported by the Key Project of Chinese National Programs for Fundamental Research and Development (973 Program, 2012CBA01306) and the National Natural Science Foundation of China (81471429). We thank the study participants who donated blood and follicular fluid samples for this study.
Polycystic ovary syndrome (PCOS) is a common reproductive disease with high heterogeneity. The role of excess androgen in PCOS etiology remains disputed, since around 20%–50% of PCOS women do not display hyperandrogenemia. The microenvironment of the ovary critically influences follicular development. In the present study, we assessed the role of androgen in PCOS by investigating whether excessive follicular fluid androgen was present in PCOS patients with normal serum androgen levels and influenced by follicular fluid insulin resistance (IR). Follicular fluid samples of 105 women with PCOS and 105 controls were collected. Levels of steroid hormones, glucose and insulin in the follicular fluid were examined and compared with data from serum biochemistry tests. We found that 64.9% (63/97) of PCOS patients with normal serum androgen levels displayed abnormally high follicular fluid androgen level. The follicular fluid androgen level was positively correlated with follicular fluid IR within a certain range and follicular fluid estrogen-to-testosterone (E2/T) ratio was significantly reduced in these patients. These results indicated that there existed a subgroup of PCOS patients who displayed excessive follicular fluid androgen and IR despite their normal circulating testosterone (T) levels. Our study highlights the importance of ovary hyperandrogenism and IR in the etiology of PCOS.
Nasimi Shad A, Moghbeli M. Integrins as the pivotal regulators of cisplatin response in tumor cells. Cell Commun Signal, 2024, 22(1): 265.
DOI:10.1186/s12964-024-01648-0
2.
Li J, Peng L, Chen Q, et al. Integrin β1 in Pancreatic Cancer: Expressions, Functions, and Clinical Implications. Cancers (Basel), 2022, 14(14): 3377.
DOI:10.3390/cancers14143377
3.
Dötzer K, Schlüter F, Koch FEV, et al. Integrin α2β1 Represents a Prognostic and Predictive Biomarker in Primary Ovarian Cancer. Biomedicines, 2021, 9(3): 289.
DOI:10.3390/biomedicines9030289
4.
Khine HEE, Ecoy GAU, Roytrakul S, et al. Chemosensitizing activity of peptide from Lentinus squarrosulus (Mont.) on cisplatin-induced apoptosis in human lung cancer cells. Sci Rep, 2021, 11(1): 4060.
DOI:10.1038/s41598-021-83606-1
5.
Moreira AM, Pereira J, Melo S, et al. The Extracellular Matrix: An Accomplice in Gastric Cancer Development and Progression. Cells, 2020, 9(2): 394.
DOI:10.3390/cells9020394
6.
Haeger A, Alexander S, Vullings M, et al. Collective cancer invasion forms an integrin-dependent radioresistant niche. J Exp Med, 2020, 217(1): e20181184.
DOI:10.1084/jem.20181184
7.
Yang XG, Zhu LC, Wang YJ, et al. Current Advance of Therapeutic Agents in Clinical Trials Potentially Targeting Tumor Plasticity. Front Oncol, 2019, 9: 887.
DOI:10.3389/fonc.2019.00887
8.
Manini I, Ruaro ME, Sgarra R, et al. Semaphorin-7A on Exosomes: A Promigratory Signal in the Glioma Microenvironment. Cancers (Basel), 2019, 11(6): 758.
DOI:10.3390/cancers11060758
9.
Raab-Westphal S, Marshall JF, Goodman SL. Integrins as Therapeutic Targets: Successes and Cancers. Cancers (Basel), 2017, 9(9): 110.
DOI:10.3390/cancers9090110